U.S. Markets close in 5 hrs 3 mins

If You Had Bought Natus Medical (NASDAQ:BABY) Stock A Year Ago, You'd Be Sitting On A 27% Loss, Today

Simply Wall St

It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Investors in Natus Medical Incorporated (NASDAQ:BABY) have tasted that bitter downside in the last year, as the share price dropped 27%. That's well bellow the market return of 3.4%. Longer term shareholders haven't suffered as badly, since the stock is down a comparatively less painful 17% in three years.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Check out our latest analysis for Natus Medical

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Unfortunately Natus Medical reported an EPS drop of 105% for the last year. Readers should not this outcome was influenced by the impact of extraordinary items on EPS. In fact, it actually made a loss over the last twelve months. The share price fall of 27% isn't as bad as the reduction in earnings per share. It may have been that the weak EPS was not as bad as some had feared.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

NasdaqGS:BABY Past and Future Earnings, May 24th 2019

Dive deeper into Natus Medical's key metrics by checking this interactive graph of Natus Medical's earnings, revenue and cash flow.

A Different Perspective

While the broader market gained around 3.4% in the last year, Natus Medical shareholders lost 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 1.2%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you would like to research Natus Medical in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.